AR095496A1 - Formulaciones de anticuerpos anti-receptor de prolactina - Google Patents

Formulaciones de anticuerpos anti-receptor de prolactina

Info

Publication number
AR095496A1
AR095496A1 ARP140101101A ARP140101101A AR095496A1 AR 095496 A1 AR095496 A1 AR 095496A1 AR P140101101 A ARP140101101 A AR P140101101A AR P140101101 A ARP140101101 A AR P140101101A AR 095496 A1 AR095496 A1 AR 095496A1
Authority
AR
Argentina
Prior art keywords
prolactin
formulations
receiver
antibodies anti
prlr antibody
Prior art date
Application number
ARP140101101A
Other languages
English (en)
Spanish (es)
Inventor
Niu Jianjie
Ma Xinghang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR095496A1 publication Critical patent/AR095496A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ARP140101101A 2013-03-15 2014-03-14 Formulaciones de anticuerpos anti-receptor de prolactina AR095496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361799629P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095496A1 true AR095496A1 (es) 2015-10-21

Family

ID=50678293

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101101A AR095496A1 (es) 2013-03-15 2014-03-14 Formulaciones de anticuerpos anti-receptor de prolactina

Country Status (10)

Country Link
US (2) US9023357B2 (2)
EP (1) EP2968538A1 (2)
JP (1) JP2016515515A (2)
CN (1) CN105025925A (2)
AR (1) AR095496A1 (2)
CA (1) CA2906101A1 (2)
HK (1) HK1215175A1 (2)
TW (1) TW201513882A (2)
UY (1) UY35460A (2)
WO (1) WO2014143909A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
TW201513882A (zh) * 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
SG10202012778YA (en) 2015-12-18 2021-01-28 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
IL249795B (en) 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of an immunoglobulin preparation g
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3518971A4 (en) 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
MY197202A (en) * 2017-03-16 2023-05-31 Lg Chemical Ltd A liquid formulation of anti-tnf alpha antibody
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
CN112020365A (zh) * 2018-01-26 2020-12-01 豪夫迈·罗氏有限公司 组合物和使用方法
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
TW202432601A (zh) 2022-11-07 2024-08-16 美商上游生物公司 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR064801A1 (es) * 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
RU2495882C2 (ru) * 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
CN105037549B (zh) * 2007-01-11 2018-09-28 诺和诺德公司 抗-kir抗体、制剂及其应用
JP2011500086A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
ES2531385T3 (es) * 2008-09-19 2015-03-13 Hoffmann La Roche Formulación que comprende un anticuerpo contra la selectina P
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
TW201513882A (zh) * 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物

Also Published As

Publication number Publication date
CN105025925A (zh) 2015-11-04
WO2014143909A1 (en) 2014-09-18
HK1215175A1 (zh) 2016-08-19
CA2906101A1 (en) 2014-09-18
US9023357B2 (en) 2015-05-05
UY35460A (es) 2014-10-31
TW201513882A (zh) 2015-04-16
JP2016515515A (ja) 2016-05-30
US20140271659A1 (en) 2014-09-18
US20160002342A1 (en) 2016-01-07
EP2968538A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
AR095496A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina
AR092401A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr)
AR130402A2 (es) Formulaciones de anticuerpos anti-pdl1
AR124140A2 (es) Formulaciones de anticuerpos
PE20181400A1 (es) Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab
HRP20191299T1 (hr) Formulacije protutijela
AR108240A1 (es) Formulaciones que contienen anticuerpos
ES2676205T3 (es) Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
PE20190405A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4beta7
NZ630885A (en) Antibody formulation
MX385109B (es) Formulaciones de anticuerpos.
PE20141413A1 (es) Formulaciones de anticuerpo y metodos
RU2013148119A (ru) Лиофилизированный препарат ботулотоксина
PE20142407A1 (es) Formulacion de anticuerpos
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
EA201490804A1 (ru) Препараты этанерцепта, стабилизированные хлоридом натрия
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
AR098168A1 (es) Formulación estable de insulina glulisina
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
AR095396A1 (es) Formulaciones de anticuerpo
GT201500046A (es) Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
PE20151524A1 (es) FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida

Legal Events

Date Code Title Description
FB Suspension of granting procedure